Abiopharma

🔍 AKKARAJU SRINIVAS (Executive)

Company: vTv Therapeutics Inc. (VTVT)

Report Date: 2025-09-03

Detailed Transactions and Holdings:

• Acquired 655,523 shares of Pre-Funded Warrants (Right to Buy) at $0.01 per share (Derivative)
  Date: 2025-09-03 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,548,101.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F2, F3
• Acquired 655,523 shares of Warrant to Purchase Class A Common Stock (Right to Buy) at $22.71 per share (Derivative)
  Date: 2025-09-03 | Code: A | equity_swap_involved: 0 | shares_owned_after: 655,523.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4, F4, F3

Footnotes:

• F1: On August 29, 2025, Samsara BioCapital, L.P. ("Samsara LP") entered into a securities purchase agreement with the Issuer pursuant to which Samsara LP purchased pre-funded warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock and common warrants exercisable for up to 655,523 shares of the Issuer's Class A Common Stock.
• F2: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.
• F3: These securities are held by Samsara LP. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
• F4: The Common Warrants are immediately exercisable and expire on the earlier of (i) September 3, 2030 and (ii) the date that is 90 days after the date the Exercise Conditions (as defined in the Common Warrants) have been met. A holder of Common Warrants may not exercise the Common Warrants if the holder, together with its Attribution Parties (as defined in the Common Warrants), would beneficially own more than 9.99% of the number of shares of Class A Common Stock outstanding immediately after giving effect to such exercise.